Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Stephane De Botton, Thomas Cluzeau, MDPhD, Carlos Enrique Vigil, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Jane L. Liesveld, MD, Pierre Fenaux, MD PhD, Thorsten Braun, MD PhD, Anne Banos, MD, Michael R. Savona, MD, Don Park, MD, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Eytan M. Stein, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134600

Published: 2020

Journal Articles

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Eytan M. Stein, MD, Stephane De Botton, Thomas Cluzeau, MDPhD, Arnaud Pigneux, MD PhD, Jane L. Liesveld, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Thorsten Braun, MD PhD, Dale L. Bixby, MD, Gail J. Roboz, MD, Delphine Lebon, MD, Mael Heiblig, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Pierre Peterlin, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-134602

Published: 2020

Journal Articles

Selection of RARA-Positive Newly Diagnosed Unfit AML Patients with Elevated RARA Gene Expression Enriches for Features Associated with Primary Resistance to Venetoclax and Clinical Response to SY-1425, a Potent and Selective RARα Agonist, Plus Azacitidine

Christopher Fiore, PhD, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Kate Madigan, MD, Matthew Eaton, PhD, Graeme Hodgson, PhD, David A. Roth, MD, Qing Kang-Fortner, PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137323

Published: 2020

Journal Articles

Assessing the Risk of Cardiac Toxicity after Contemporary Treatment for Hodgkin Lymphoma (HL): A Multidisciplinary Systematic Review

Julie Fu, MD MA, Jenica Upshaw, MDMS, Michael J. Kelly, MD MPH, MS, Joshua T Cohen, PhD, Tully Saunders, MBA, Andrew M Evens, DO, MSc, FACP, Susan K Parsons, MDMRP

Blood (2016) 128 (22): 3564.

https://doi.org/10.1182/blood.V128.22.3564.3564

Published: 2016

Journal Articles

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Michael J. Kelly, MD MPH, MS, Susan K Parsons, MDMRP, David C. Hodgson, MD, Joshua T Cohen, PhD, Jennifer M Yeh, MD PhD, Jeremy S. Abramson, MD, Debra L. Friedman, MD MS, Tara O Henderson, MDMPH, Peter W Johnson, MD, Stephen G Pauker, MD, John M. Raemaekers, MD PhD, Jane N. Winter, MD, Kara M. Kelly, MD, Ralph M. Meyer, MD, Sharon M Castellino, MD, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 2635.

https://doi.org/10.1182/blood.V126.23.2635.2635

Published: 2015

Journal Articles

Cranial Radiation for Pediatric T-Cell Acute Lymphoblastic Leukemia: A Decision Analysis

Michael J. Kelly, MD MPH, MS, Stephen G. Pauker, MD, Susan K. Parsons, MD MRP

Blood (2014) 124 (21): 3700.

https://doi.org/10.1182/blood.V124.21.3700.3700

Published: 2014

NARROW

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Selection of RARA-Positive Newly Diagnosed Unfit AML Patients with Elevated RARA Gene Expression Enriches for Features Associated with Primary Resistance to Venetoclax and Clinical Response to SY-1425, a Potent and Selective RARα Agonist, Plus Azacitidine

Assessing the Risk of Cardiac Toxicity after Contemporary Treatment for Hodgkin Lymphoma (HL): A Multidisciplinary Systematic Review

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Cranial Radiation for Pediatric T-Cell Acute Lymphoblastic Leukemia: A Decision Analysis

Email alerts

ASH Publications

American Society of Hematology

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Selection of RARA-Positive Newly Diagnosed Unfit AML Patients with Elevated RARA Gene Expression Enriches for Features Associated with Primary Resistance to Venetoclax and Clinical Response to SY-1425, a Potent and Selective RARα Agonist, Plus Azacitidine

Assessing the Risk of Cardiac Toxicity after Contemporary Treatment for Hodgkin Lymphoma (HL): A Multidisciplinary Systematic Review

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Cranial Radiation for Pediatric T-Cell Acute Lymphoblastic Leukemia: A Decision Analysis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only